Aclarion Inc - ACON STOCK NEWS

Aclarion, Inc. (Nasdaq: ACON) has expanded its Clinical Utility and Economic (CLUE) Trial to New Jersey, with Dr. Justin Kubeck of Ocean Pain and Spine joining the study. The CLUE trial aims to demonstrate how Nociscan's AI-generated data impacts treatment decisions for chronic low back pain. Nociscan is Aclarion's SaaS platform that noninvasively helps physicians identify painful discs in the lumbar spine by quantifying chemical biomarkers associated with disc pain.

Dr. Kubeck is the second surgeon to join CLUE, following Dr. John Keller in Michigan. Aclarion expects more spine surgeons to participate, rapidly providing data to payers on Nociscan's impact on treatment planning. The company aims to address the global issue of degenerative spine disease and low back pain, which affects 266 million people worldwide.

Aclarion (NASDAQ: ACON) has launched the Clinical Utility and Economic (CLUE) Trial to quantify how often Nociscan's AI-generated biomarker data changes surgical treatment plans for chronic low back pain. The multi-center study aims to provide insights into the real-world value of Nociscan as a decision support tool. Surgeons will determine their treatment plan before and after receiving Nociscan data, allowing Aclarion to assess the tool's influence on surgical decisions.

The CLUE trial complements the ongoing CLARITY study, which focuses on demonstrating improved surgical outcomes with Nociscan. CLUE's format is inspired by HeartFlow's evidence strategy, which led to changes in coronary artery disease assessment. Aclarion expects multiple physicians and sites to enroll in CLUE in the coming months, adding practical data to their expanding clinical evidence base.

Aclarion (Nasdaq: ACON), a healthcare technology company specializing in chronic low back pain diagnosis, has announced its participation in the upcoming Virtual Investor Summit on August 20th, 2024. The company, which utilizes biomarkers and proprietary augmented intelligence algorithms to assist physicians in locating chronic low back pain sources, will be presenting at 4:00 PM ET.

Investors interested in attending the presentation can access it via the provided webcast link. Additionally, there's an opportunity for one-on-one meetings with Aclarion's management team, which can be arranged through the Investor Summit Group's registration process.

Aclarion, Inc. (Nasdaq: ACON) has announced its first commercial agreement in Michigan with Sheridan Community Hospital. This agreement brings Nociscan, Aclarion's innovative solution for identifying chronic low back pain, to central Michigan and to Dr. John Keller, a leading neurosurgeon and Aclarion medical advisor.

Nociscan is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. It objectively quantifies chemical biomarkers associated with disc pain, providing critical insights when used with other diagnostic tools.

This agreement is part of Aclarion's strategy to expand access to Nociscan in the US market, following recent insurance coverage announcements in the UK. It represents a step towards potential payer coverage in the United States.

Aclarion (NASDAQ: ACON) has achieved a significant milestone by securing coverage for its Nociscan technology from Vitality, the third major private health insurer in the UK. This addition means Aclarion now has coverage from 3 of the 4 largest private health insurers in the UK, providing access to nearly 60% of patients with private health insurance in the Greater London market.

Nociscan, a SaaS platform that helps physicians identify the location of chronic low back pain, is gaining traction in the UK healthcare market. The London Clinic, a renowned independent hospital, has played a important role in demonstrating Nociscan's value and securing payer coverage. Aclarion's CEO, Brent Ness, expects this success to be replicated across their 10 KOL sites globally.

With private medical insurance becoming increasingly popular in the UK, these coverage decisions represent a significant shift in Aclarion's business model, providing a clear path to commercialization in the UK market.

Aclarion achieved a significant milestone with Aviva, a top UK private medical insurer, covering Nociscan, its AI-driven diagnostic tool for chronic low back pain. This coverage extends Nociscan's availability to 45% of patients with private insurance in Greater London, joining AXA, which already provides coverage. This development marks a important step in gaining broader market adoption and potential value creation for Aclarion. Nociscan, the first evidence-supported SaaS platform, helps physicians noninvasively identify painful lumbar discs by quantifying chemical biomarkers. The London Clinic is among the premier institutions adopting this technology.

Aclarion (Nasdaq: ACON) announced the first payer coverage of its Nociscan technology by AXA in Greater London, UK, in cooperation with The London Clinic. AXA, the second largest provider of private medical insurance in the UK, covers about 30% of the private medical insurance market with around 3 million insured clients. This endorsement marks a significant milestone for Aclarion, paving the way for widescale commercialization and broader adoption of Nociscan, a tool designed to assist physicians in diagnosing chronic low back pain. The decision is expected to improve patient outcomes significantly and drive future revenue growth for Aclarion.

Aclarion has extended its commercial agreement with The London Clinic to increase the use of Nociscan, a technology that helps identify the location of chronic low back pain. The new contract sets a higher price for Nociscan and includes efforts to secure payer coverage from private health insurers. The London Clinic, a renowned private hospital, will also work to expand access to Nociscan for patients and referring physicians throughout Greater London. The extension follows compelling results from an initial evaluation involving 20 patients. CEO Brent Ness highlighted the importance of the UK market and expressed confidence in achieving similar results in the U.S. market.

Aclarion's Nociscan Solution will be utilized in the LIFEHAB Trial in Norway, a randomized controlled trial comparing lumbar interbody fusion surgery with multidisciplinary rehabilitation for chronic low back pain. The trial aims to enroll 202 patients with back pain greater than 1 year in duration. Nociscan is the first evidence-supported SaaS platform to help physicians distinguish between painful and nonpainful discs in the lumbar spine using chemical biomarkers and proprietary algorithms. Aclarion sees this trial as a significant step towards successful reimbursement in Norway's national health insurance system, targeting enrollment to start in the second quarter of 2024.